​

Funding Round

Series B - eTheRNA immunotherapies

Series B - eTheRNA immunotherapies

Investment Firm

Overview

eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.

Announced Date

Aug 23, 2022

Funding Type

Series B

Highlights

Location

Europe

Social

Investor Lead

Novalis LifeSciences

Novalis LifeSciences

Novalis LifeSciences is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

7

Investor Name
Participant InvestorFund+
Participant InvestorKenneth Chien
Participant InvestorPMV
Participant InvestorEQT Life Sciences
Participant InvestorOmega Funds

Round Details and Background

eTheRNA immunotherapies raised $38869747 on 2022-08-23 in Series B

eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 22, 2021
Grant - eTheRNA immunotherapies
1-6.9M
Aug 23, 2022
Series B - eTheRNA immunotherapies
7-38.9M
Sep 25, 2017
Grant - eTheRNA immunotherapies
1-1.2M
Mar 14, 2016
Series A - eTheRNA immunotherapies
4-26.6M

Recent Activity

There is no recent news or activity for this profile.